GlassScriptPhysician profile
Nora D Hogan
NPI 1568592582
$11,428.07
in general payments reported to CMS, 2019-2025
68 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,701 · 2022: $1,605 · 2023: $2,151 · 2024: $2,991 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,393 · Long Term Medical Supply Or Device Loan: $1,530 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,393.07 |
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,026.90 | 2023-2025 | |
| Janssen Biotech, INC. | $928.18 | 2021-2025 | Erleada, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $632.68 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $611.82 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $541.34 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Eisai INC. | $491.25 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $424.71 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Aveo Pharmaceuticals, INC. | $364.57 | 2022-2025 | Fotivda |
| Astellas Pharma US INC | $337.92 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Pfizer INC. | $276.44 | 2022-2025 | |
| Celgene Corporation | $276.00 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $274.73 | 2021-2025 | |
| Daiichi Sankyo INC. | $268.31 | 2022-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $243.05 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $242.57 | 2021-2025 | Zejula, Jemperli, Ojjaara |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $215.97 | 2021-2025 | Beleodaq |
| Pharmacyclics LLC, An Abbvie Company | $192.67 | 2021-2023 | Imbruvica |
| Puma Biotechnology, INC. | $171.51 | 2021-2025 | |
| Seagen INC. | $165.02 | 2021-2023 | Padcev, Tukysa |
| Genentech USA, INC. | $163.99 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Pharmacosmos Therapeutics INC. | $154.58 | 2021-2025 | Monoferric |
| Boston Scientific Corporation | $144.95 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.06 | 2021-2025 | Ninlaro, Vpriv, Alunbrig |
| Kite Pharma, INC. | $125.91 | 2021-2024 | Yescarta |
| Genzyme Corporation | $120.80 | 2021-2025 | |
| Array Biopharma INC | $114.29 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Abbvie INC. | $94.47 | 2021-2025 | |
| Gilead Sciences, INC. | $92.88 | 2022-2024 | Trodelvy |
| Genmab U.S., INC. | $90.69 | 2023-2024 | Tivdak, Epkinly |
| Adc Therapeutics America, INC. | $84.95 | 2024-2025 | |
| Sobi, INC | $83.93 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $78.35 | 2023-2025 | |
| Mirati Therapeutics, INC. | $75.58 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $73.64 | 2023-2024 | Clonoseq |
| Epizyme, INC. | $70.66 | 2021-2023 | Tazverik |
| Stemline Therapeutics INC. | $64.40 | 2023-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $62.47 | 2021-2025 | |
| Tempus Ai, INC | $59.97 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $51.94 | 2023-2024 | |
| Beigene USA, INC. | $46.39 | 2022-2023 | Brukinsa |
| Morphosys, US INC. | $43.14 | 2021-2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.23 | 2021-2023 | Gilotrif |
| G1 Therapeutics, INC. | $42.03 | 2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $40.59 | 2021-2024 | Rezlidhia, Tavalisse |
| Alnylam Pharmaceuticals INC. | $40.16 | 2022-2024 | Givlaari |
| Beone Medicines USA, INC. | $39.63 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $39.53 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $36.70 | 2023 | Libtayo |
| Karyopharm Therapeutics INC. | $32.74 | 2021-2023 | Xpovio |
| Kyowa Kirin, INC. | $32.62 | 2023-2024 | Poteligeo |
| Geron Corporation | $31.74 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $29.72 | 2025 | Zoladex |
| Exelixis INC. | $28.77 | 2021 | |
| Deciphera Pharmaceuticals INC. | $25.48 | 2021-2022 | |
| Spectrum Pharmaceuticals INC. | $24.20 | 2024 | Rolvedon |
| Sun Pharmaceutical Industries INC. | $22.16 | 2021 | |
| Eusa Pharma (US) LLC | $20.47 | 2022 | |
| Legend Biotech USA INC. | $20.18 | 2024 | |
| Dendreon Pharmaceuticals LLC | $18.47 | 2024 | Provenge |
| Amneal Pharmaceuticals LLC | $17.00 | 2025 | Alymsys |
| Springworks Therapeutics, INC. | $16.89 | 2025 | Ogsiveo |
| Blueprint Medicines Corporation | $16.54 | 2021 | |
| Sumitomo Pharma America, INC. | $15.23 | 2025 | Orgovyx |
| Tg Therapeutics, INC. | $14.50 | 2022 | |
| Agios Pharmaceuticals, INC. | $14.32 | 2023 | Pyrukynd |
| Immunogen, INC. | $14.17 | 2023 | Elahere |
| Bio Products Laboratory USA, INC. | $13.75 | 2021 | |
| Myovant Sciences INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.